Document:

EXHIBIT 10.12

 

Entera
Bio Ltd.

 

[date]

 

Dear [please
insert name]

 

 

 

Re:Indemnification
Letter between Entera Bio Ltd. and [name] (the “Indemnification Letter”)

 

You are
or have been appointed as a director or office holder as such terms are defined in the Israeli Companies Law – 1999 (the
“Companies Law”) (collectively, an “Office Holder”) of Entera Bio Ltd. (the “Company”),
and in order to enhance your service to the Company in an effective manner, the Company desires to provide hereunder for your
indemnification to the fullest extent permitted by law. The indemnification provided for herein will also apply if permitted by
the Companies Law to any “action” (as such term is defined below) taken by you in your capacity as a director, officer
and/or employee of any other company controlled directly or indirectly by the Company (“Subsidiary”) or in
your capacity as a director, or observer at board of directors’ meetings of a company not controlled by the Company but
where your appointment as a director or observer results directly from the Company’s holdings in such company (“Affiliate”)
and references herein to the Company shall encompass such roles, as applicable.

 

This letter
is a supplement to and in furtherance of the indemnification provisions of the Articles of Association of the Company (as may
be amended from time to time) and shall not be deemed a substitute therefor, nor to diminish or abrogate any of your rights thereunder.

 

In consideration
of you continuing to serve the Company, the Company hereby agrees as follows:

 

1.             The Company hereby undertakes to indemnify you to the maximum extent permitted by the Companies Law in respect of the following:

 

1.1.  any financial obligation or liability imposed on, or incurred by you in favor of another person and/or legal entity, including
any government office by, or expended by you as a result of, a court judgment, including a settlement or an arbitrator’s
decisions approved by a court of law, in respect of any act or omission (“action”) taken or made by you in
your capacity as an Office Holder of the Company or any Subsidiary; and

 

1.2.  all reasonable legal expenses including attorney’s fees expended by you or charged to you by a court of law, including
reasonable attorneys’ fees and all other costs, expenses and obligations incurred in connection with investigating, defending,
being a witness in or participating in (including on appeal), or preparing to defend to be a witness in or participate, in any
action, suit, proceeding, alternative dispute resolution mechanism, hearing, inquiry or investigation brought against you by the
Company or on its behalf or by another person, or in any criminal prosecution in which you are acquitted, or in any criminal prosecution
of a crime which does not require proof of criminal intent in which you are convicted, all in respect of actions taken by you
in your capacity as an Office Holder of the Company or of any Subsidiary; and

 

     

    - 1  -

    

1.3.  all reasonable expenses, including attorneys’ fees, expended by you as a result of an investigation or a proceeding
instituted against you by a competent authority, provided that such investigation or proceeding is “concluded without the
filing of an indictment against you” (as defined in the Companies Law) and “without any financial liability imposed
on you in lieu of criminal proceedings” (as defined in the Companies Law), or that is concluded with the imposition of a
financial liability in lieu of criminal proceedings but relates to a criminal offense that does not require proof of criminal
intent or in connection with a financial sanction imposed on you in your capacity as an Office Holder of the Company or of any
Subsidiary; and

 

1.4.  A payment which you are obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Israeli Securities
Law, 1968, as amended (the “Securities Law”), if applicable, and reasonable litigation expenses, including
attorney fees, that you incurred in connection with a proceeding under Chapters H’3, H’4 or I’1 of the Securities
Law, if applicable, or under Article D of the Fourth Chapter, Ninth Part of the Companies Law, if applicable, including reasonable
legal expenses, which term includes attorney fees; and

 

1.5.  any other circumstances arising under the law in respect of which the Company may indemnify an Office Holder of the Company,
(including, without limitation, Section 50P(b)(2) of the Israeli Restrictive Trade Practices Law, 5758-1988).

 

2.             Notwithstanding the aforesaid, the Company will not indemnify you for any amount you may be obligated to pay in respect
of:

 

2.1.  a breach of your duty of loyalty to the Company or any Subsidiary, except, to the extent permitted by the Companies Law,
for a breach of a duty of loyalty to the Company or any Subsidiary while acting in good faith and having reasonable cause to assume
that such act would not prejudice the interests of the Company or any Subsidiary, as applicable;

 

2.2.  a willful or reckless breach of the duty of care, other than a breach committed solely by negligence;

 

2.3.  an action taken or not taken with the intent of unlawfully realizing personal gain; 

 

2.4.  a fine or penalty imposed upon you for an offense; and

 

2.5.  a counterclaim made by the Company or any Subsidiary or in their names in connection with a claim against the Company or
any Subsidiary filed by an Indemnitee.

 

In any such
case under this Section 2, a determination of non-indemnification by the Company shall only be made if it is determined upon final
adjudication of a court of competent jurisdiction that you are not lawfully entitled to such indemnification.

 

3.             To the fullest extent permitted by law, the Company shall make available all amounts needed in accordance with Section
1 above on the date on which such amounts are first payable by you (“Time of Indebtedness”), or as soon as
possible, but in any event not later than five (5) Business Days following your written demand to the Company, and with respect
to items referred to in Section 1.2 and 1.3 above, even prior to a court or other tribunal decision. Subject to applicable law
and the other provisions hereof, the Company shall advance reasonable expenses incurred by you in connection with a claim relating
to any event that is indemnifiable hereunder. Advances given to cover reasonable expenses in criminal proceedings will be repaid
by you to the Company, within ten (10) Business Days as of the court’s decision, if you are found guilty of a crime which
requires proof of criminal intent or if a financial liability was imposed in lieu of a criminal proceeding for a crime which requires
a finding of criminal intent. Other advances will be repaid by you to the Company if it is determined by a court of competent
jurisdiction that you are not lawfully entitled to such 

 

     

    - 2  -

    

indemnification.
For purposes of this Indemnification Letter, “Business Days” means days on which customer services are provided
by a majority of the major commercial banks in Israel.

 

As part of the aforementioned
undertaking, the Company will make available to you any security or guarantee that you may be required to post in accordance with
an interim decision given by a court or an arbitrator, including for the purpose of substituting liens imposed on your assets.

 

4.             The
Company will indemnify you even if at the relevant Time of Indebtedness you are no longer an Office Holder of the Company or any
Subsidiary provided that the obligations are in respect of actions taken by you while you were an Office Holder of the Company
or any Subsidiary as aforesaid, and in such capacity.

 

5.             Subject
to the applicable law, including, without limitation, the Companies Law, the indemnification will be limited to the matters mentioned
in Section 1.2 through 1.5 above and to the matters mentioned in Section 1.1 above insofar as they result from, or are connected
to, your actions in the following matters, which are deemed by the Company’s Board of Directors (the “Board”),
based on the current activity of the Company, to be foreseeable at the date hereof: 

 

5.1.  The offering or sale of securities by the Company and/or by a shareholder to the public and/or to private investors or
the offer by the Company to purchase securities from holders thereof pursuant to a prospectus, agreements, notices, reports, tenders
and/or other proceedings and violations of securities laws of any jurisdiction, including without limitation, fraudulent disclosure
claims and other claims relating to relationships with investors and the investment community;

 

5.2.  Actions in connection with investments the Company, Affiliates and/or Subsidiaries make in other corporations whether before
and/or after the investment is made, entering into the transaction, the execution, development and monitoring thereof, including
actions taken by you in the name of the Company, Affiliates and/or Subsidiaries as a director, officer and/or board observer of
the corporation which is the subject of the transaction and the like;

 

5.3.  The sale, purchase and holding of negotiable securities or other investments for or in the name of the Company, Affiliates
and/or any Subsidiary;

 

5.4.  Actions in connection with any sale of the assets of the Company or the acquisition of any other entity or the Company,
Affiliate and/or any Subsidiary by another entity by means of merger or consolidation resulting in the exchange of the outstanding
shares of the Company, Affiliate and/or any Subsidiary or the liquidation of the Company, the issuance of shares or securities
exercisable into shares of the Company, changing the share capital of the Company, formation of subsidiaries, reorganization,
winding up or sale of all or part of the business, operations or shares of the Company;

 

5.5.  Actions in connection with the sale of the operations and/or business, or part thereof, of the Company, Affiliate and/or
any Subsidiary;

 

5.6.  Actions in connection with the purchase, licensing or acquisition of rights in products, assets or technologies of other
persons or legal entities, and the sale, licensing or grant of license in the same to other persons or legal entities;

 

5.7.  Actions in connection with the purchase or sale of companies, legal entities or assets, and the division or consolidation
thereof;

 

5.8.  Actions taken in connection with labor relations and/or employment matters in the Company, Affiliate and/or any Subsidiary
and trade relations of the Company, Affiliate and/or any Subsidiary, including with employees, independent contractors, customers,
suppliers and various service providers;

 

     

    - 3  -

    

5.9.  Actions in connection with the conduct of clinical trials and/or testing, development, testing or manufacturing of products
developed by the Company, Affiliate and/or any Subsidiary or in connection with the distribution, sale, license or use of such
products, including without limitations in connection with professional liability and product liability claims;

 

5.10.
 Actions taken in connection with the intellectual property of the Company, Affiliate and/or any Subsidiary and its protection,
including the registration or assertion of rights to intellectual property and the defense of claims related to intellectual property;

 

5.11.
 Actions taken pursuant to or in accordance with the policies and procedures of the Company, Affiliate and/or any Subsidiary, whether
such policies and procedures are published or not;

 

5.12.
 Approval of corporate actions, including the approval of acts of the Company’s management, its guidance and its supervision;

 

5.13.
 Claims of failure to exercise business judgment and a reasonable level of proficiency, expertise and care in regard of the Company’s
business;

 

5.14.
 Violations of laws requiring the Company to obtain regulatory and governmental licenses, permits and authorization in any jurisdiction;

 

5.15.
 Claims in connection with publishing or providing any information, including any filings with governmental authorities (including,
without limitation, the Israeli income tax authorities, National Insurance Institute of Israel and the Israeli Companies Registrar),
on behalf of the Company, in the circumstances required under applicable laws;

 

5.16.
 Claims in connection with the preparation or providing of any annual or quarterly financial statements, profit and loss statements,
balance sheets and similar financial information;

 

5.17.
  Any claim or demand made by any lenders or other creditors or for monies borrowed by, or other indebtedness of, the Company or
its Affiliates and/or Subsidiaries;

 

5.18.
  Actions resulting in bodily injury or harm, illness, death, or property loss, including the loss of use thereof;

 

5.19.
 Actions concerning the approval of transactions of the Company, Affiliate and/or any Subsidiaries with Office Holders and/or holders
of controlling interests in the Company, Affiliate and/or any Subsidiaries;

 

5.20.
  Participation and/or non-participation at the Board and/or Board committees meetings, bona fide expression of opinion and/or voting
and/or abstention from voting at the Board and/or Board committees meetings;

 

5.21.
  The Company’s interaction with the tax authorities, the Company’s and the subsidiaries’ shareholders, employees,
creditors and other third parties, including, but not limited to: (i) failure to remit tax withheld in connection with the Company’s
and its Subsidiaries’ and/or Affiliate’s employees’ compensation and benefits; (ii) failure to remit to third
parties any amount deducted from the payments due to the Company’s and its Subsidiaries’ and/or Affiliate’s
employees; (iii) failure to pay royalties due to third parties in compliance with the agreement(s) entered into between the Company
and its Subsidiaries and/or Affiliates with such third parties; and (iv) failure to pay monetary liabilities to third parties
relating to loans received by the Company and its Subsidiaries and/or Affiliates;

 

     

    - 4  -

    

5.22.
Actions taken in connection with the intellectual property rights of the Company and its Subsidiaries and/or Affiliates and its
protection, including, but not limited to confidential information, patents, copyrights, design rights, service marks, trade secrets,
copyrights, misappropriation of ideas;

 

5.23.
Actions in connection with the conduct of clinical trials and/or testing, development, or manufacturing of products developed
by the Company and its Subsidiaries and/or Affiliates or by third parties on behalf of the Company and its Subsidiaries and/or
Affiliates and/or in connection with the sale, distribution, license or use of such products;

 

5.24.
Actions relating to an offer or issuance of securities of the Company and its Subsidiaries and/or Affiliates to the public by
prospectus or privately by private placement, in Israel or abroad, including the details that shall be set forth in the documents
in connection with execution thereof;

 

5.25.
Actions and/or reports required by law, if and when the Company shall become a public company whose shares are offered to the
public and/or traded on a stock exchange in Israel or abroad and/or as required under law and contract with respect to a private
company;

 

5.26.
Resolutions and/or actions and/or reports made in the ordinary course of business and relating to the management of the Company’s
business and/or the business of a Subsidiary or an Affiliate;

 

5.27.
Resolutions and/or actions relating to environmental and public health matters of the Company and/or of a Subsidiary or an Affiliate;

 

5.28.
Resolutions and/or actions relating to patents, trademarks, copyrights and other intellectual property and/or in regard to the
violation of the same;

 

5.29.
Acts or omissions not covered by product liability insurance;

 

5.30.
Resolutions and/or actions relating to investments in the Company and/or its subsidiaries and/or Affiliates and/or the purchase
or sale of assets, including the purchase or sale of companies and/or businesses, and/or investments in corporate or other entities
and/or investments in traded securities and/or any other form of investment;

 

5.31.
Resolutions and/or actions relating to transactions of the Company and/or of a Subsidiary or an Affiliate with others, including
inter-company transactions, and clients, contractors, suppliers etc.;

 

5.32.
Resolutions and/or actions relating to the distribution of dividends and/or repurchase of shares or returns of capital or loans
of the Company and/or of an Affiliate;

 

5.33.
Resolutions and/or actions relating to tender offers, including actions relating to delivery of opinions in relation thereto,
of the Company and/or of an Affiliate;

 

5.34.
Resolutions and/or actions relating to the approval of transactions with officers and/or directors and/or shareholders of the
Company and/or of an Affiliate;

 

5.35.
Acts or omissions in connection with bodily injury or property damage attributed to the Company and its Subsidiaries and/or Affiliates
and/or to the Office Holder operating on the Company’s behalf;

 

5.36.
Act or omission resulting in the failure to maintain appropriate insurance and/or inadequate safety measures and/or a malpractice
of risk management;

 

5.37.
The sale of securities by the Company and its Subsidiaries and/or Affiliates and/or by a shareholder to investors or the offer
by the Company and its Subsidiaries and/or Affiliates to purchase

 

     

    - 5  -

    

securities
from the public and\or from private investors or other holders thereof pursuant to agreements, notices, reports, tenders and/or
other proceedings;

 

5.38.
The sale, purchase and holding of negotiable securities or other investments for or in the name of the Company and its Subsidiaries
and/or Affiliates;

 

5.39.
Actions in connection with the sale of the outstanding share capital and/or the operations and/or business, or part thereof, of
the Company and its Subsidiaries and/or Affiliates;

 

5.40.
Without derogating from the generality of the above, actions in connection with the purchase or sale of companies, legal entities
or assets, and the division or consolidation thereof;

 

5.41.
Actions in regard to invasion of privacy including with respect to databases and acts in regard of slander;

 

5.42.
Actions in connection with antitrust matters and/or laws and regulations relating to commercial wrong-doing;

 

5.43.
Actions in connection with the negotiations, execution, delivery and performance of agreements on behalf of the Company and its
Subsidiaries and/or Affiliates, whether written or oral;

 

5.44.
Any claim or demand made under any securities laws or by reference thereto, or related to the failure to disclose any information
in the manner or time such information is required to be disclosed pursuant to such laws, or related to inadequate or improper
disclosure of information to shareholders, or prospective shareholders, or related to the purchase, holding or disposition of
securities of the Company and its Subsidiaries and/or Affiliates or any other investment activity involving or effected by such
securities, including, for the removal of doubt, any offering of the Company and its Subsidiaries and/or Affiliate’s securities
to private investors or to the public, and listing of such securities, or the offer by the Company and its Subsidiaries and/or
Affiliates to purchase securities from the public or from private investors or other holders, and any undertakings, representations,
warranties and other obligations related to any such offering, listing or offer or to the Company and its Subsidiaries and/or
Affiliate’s status as a public company or as an issuer of securities;

 

5.45.
Any claim or demand made directly or indirectly in connection with complete or partial failure, by the Company and its Subsidiaries
and/or Affiliates, or their respective directors, officers and employees, to pay, report, keep applicable records or otherwise,
any state, municipal or foreign taxes or other mandatory payments of any nature whatsoever, including, without limitation, income,
sales, use, transfer, excise, value added, registration, severance, stamp, occupation, customs, duties, real property, personal
property, capital stock, social security, unemployment, disability, payroll or employee withholding or other withholding, including
any interest, penalty or addition thereto, whether disputed or not; and

 

5.46.
Claims by any third party suffering any personal injury and/or bodily injury and/or property damage to business or personal property
through any act or omission attributed to the Company and its Subsidiaries and/or Affiliates, or its employees, agents or other
persons acting or allegedly acting on their behalf.

 

5.47.
Violations of the Company and/or any Subsidiary and/or an Affiliate of any laws, acts, regulations and rules including without
limitation:

 

(a)               
The Israeli Income Tax Ordinance (new version), 5721-1961, and all resolutions and/or actions and/or defaults relating
to any tax law, including without limitation all payments, monetary transfers, receipts, the sale or acquisition of any assets
and all other financial 

 

     

    - 6  -

    

actions
made between the Company and its Subsidiaries and/or Affiliates and third parties including inter-company transactions and the
filing requirement relating to such actions;

 

(b)              
The Anti Money Laundering Act, 5760-2000, and all resolutions and/or actions and/or defaults relating to any related law,
including without limitation all payments, monetary transfers, receipts, the sale or acquisition of any assets and all other financial
actions made between the Company and its Subsidiaries and/or Affiliates and third parties including inter-company transactions
and the filing requirement relating to such actions;

 

(c)               
The Securities Law and all resolutions and/or actions and/or defaults relating to any securities law, including without
limitation, the disclosure of or the failure to disclose any information to any third parties including to any securities holders
of the Company and its Subsidiaries and/or Affiliates related to any sale, acquisition, issuance, distribution and any other similar
action pertaining to the Company and its Subsidiaries and/or Affiliate’s securities including any public offering, private
offering and all other offers related to the sale, purchase and acquisition of the Company and its Subsidiaries and/or Affiliate’s
securities; and

 

5.48.
Representations and warranties made in good faith in connection with the business of the Company or any Subsidiary or an Affiliates;

 

5.49.
Claims relating to the Company and its Subsidiaries and/or Affiliate’s financial reports and tax returns, including the
preparation thereof; and

 

5.50.
Any of the above taken, relating or otherwise applicable to any Subsidiary or an Affiliate.

 

6.              The indemnification that the Company undertakes towards all persons and legal entities whom it has resolved to indemnify
for the matters and in the circumstances described herein, jointly and in the aggregate, shall be the greater of : (i) $50 (fifty
million] U.S. Dollars); or (ii) an amount equal to the Company’s shareholders equity, based on the Company’s most
recent financial statements before the date on which the payment is to be made (the “Maximum Amount”), provided,
that if such amount is found insufficient to cover all amounts to which such persons and legal entities are entitled to, the abovementioned
amount shall be allocated to such persons and legal entities pro rata to the amounts to which they are so entitled. 

 

7.              The Company will not indemnify you for any liability with respect to which you have received payment by virtue of an insurance
policy or another indemnification agreement other than for amounts which are in excess of the amounts actually paid to you pursuant
to any such insurance policy or other indemnity agreement (including deductible amounts not covered by insurance policies), within
the limits set forth in Section 6 above. If you are entitled under any provision of this Indemnification Letter to indemnification
by the Company for some or a portion of the expenses actually or reasonably incurred by you, but not, however, for the total amount
thereof, the Company shall nevertheless indemnify you for the portion of such expenses to which you are entitled.

 

8.              Subject to the provisions of Sections 1 to ‎7 above, the indemnification provided for hereunder will, in each case,
cover all sums of money that you will be obligated to pay, in those circumstances for which indemnification is permitted under
the law and under this Indemnification Letter.

 

You
shall be covered by the Company’s directors and officers insurance policy, in effect from time to time (the “D&O
Policy”) and any other insurance policy or policies providing liability insurance for directors, officers, employees,
or agents or fiduciaries of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan
or other enterprise which such person serves at the request of the Company. Subject to the mandatory limitations under applicable
law, you shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage
available for any such director, officer, employee, agent or fiduciary under such policy or policies. At the time of the receipt
of a notice of a claim pursuant to the terms hereof, the Company

 

     

    - 7  -

    

shall
give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective
policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on your behalf, all
amounts payable as a result of such proceeding in accordance with the terms of such policies. The Company hereby undertakes to
notify you thirty (30) days prior to the expiration or termination of any such D&O Policy. Notwithstanding the generality
of the foregoing and except as set forth herein, the indemnification amount actually paid shall be limited to those amounts not
covered by the D&O Policy, such that you will not be entitled to payment from the Company for amounts which you have actually
obtained under the D&O Policy.

 

9.              The Company hereby acknowledges that you have now or may have in the future certain rights to indemnification, advancement
of expenses and/or insurance provided by third parties, including without limitation any investor in the Company’s shares
on behalf of which you serve as a director in the Company (the “Third Party Indemnitor”), and the Company hereby
agrees: (a) that the Company is the indemnitor of first resort (i.e., its obligations to you are primary and any obligation of
any Third Party Indemnitor to advance expenses or to provide indemnification for the same expenses or liabilities incurred by
you are secondary), and (b) that it irrevocably waives, relinquishes and releases any Third Party Indemnitor from any and all
claims against any Third Party Indemnitor for contribution, subrogation or any other recovery of any kind in respect of the subject
matters of this Indemnification Letter. Without altering or expanding any of the Company’s indemnification obligations hereunder,
the Company further agrees that no advancement or payment by any Third Party Indemnitor on your behalf with respect to any claim
for which you have sought indemnification from the Company shall affect the foregoing, and any Third Party Indemnitor shall have
a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of
yours against the Company. The Company and you agree that the Third Party Indemnitors are express third party beneficiaries of
the terms of this Section 9.

 

10.            To the extent the Company has made any payment to you under this Indemnification Letter, you agree to reimburse the Company
to the extent: (i) you receive or collect any amounts from a Third Party Indemnitor in connection with liabilities indemnified
for hereunder, including, but not limited to, any insurance policy or another indemnification agreement, or (ii) a final determination
of non-indemnification shall be given by a court of competent jurisdiction as detailed in Section 2 above. 

 

11.            The Company will be entitled to any amount collected from a third party in connection with liabilities indemnified hereunder
to be paid by you to the Company within fifteen (15) days following the receipt of the said amount. 

 

12.            In all indemnifiable circumstances, indemnification will be subject to the following:

 

12.1. You shall promptly notify the Company in writing of any legal proceedings initiated against you and of all possible or
threatened legal proceedings for which you may seek indemnification hereunder, without delay following your first becoming aware
thereof, provided, however, that your failure to notify the Company as aforesaid shall not derogate from your right to be indemnified
as provided herein, except and to the extent that such failure to provide notice materially and adversely prejudices the Company’s
ability to defend against such action. You shall deliver to the Company, or to such person as it shall advise you, without delay
all documents you receive in connection with these proceedings or possible or threatened proceedings. Similarly, you hereby commit
to advise the Company on an ongoing and current basis concerning all events which you suspect may give rise to the initiation
of legal proceedings against yourself in connection with your actions or omissions as an Office Holder of the Company or any Subsidiary,
however, your failure to notify the Company as aforesaid shall not derogate from your right to be indemnified as provided
herein except to the extent that such failure to notify causes the Company damages.

 

     

    - 8  -

    

12.2. Other than with respect to proceedings that have been initiated against you by the Company or in its name or by you against
the Company in order to assert, interpret or enforce your rights hereunder, the Company subject to your prior consent, which will
not be unreasonably withheld, shall be entitled to undertake the conduct of your defense in respect of such legal proceedings
and/or to hand over the conduct thereof to any attorney which the Company may choose for that purpose. The Company shall notify
you of any such decision to defend within seven (7) days of receipt of notice of any such proceeding.

 

12.3. The Company shall be entitled, within the context of the conduct as aforesaid, to conclude such proceedings, all as it
shall see fit, including by way of settlement. At the request of the Company, you shall execute all documents required to enable
the Company to conduct your defense in your name, and to represent you in all matters connected therewith, in accordance with
the aforesaid. 

 

12.4. For the avoidance of doubt, in the case of criminal proceedings the Company will not have the right to plead guilty in
your name or to agree to a plea-bargain in your name without your written consent. Furthermore, in a civil proceeding (whether
before a court or as a part of a compromise arrangement), the Company will not have the right to admit to any occurrences that
are not fully indemnifiable pursuant to this Indemnification Letter and/or pursuant to law, or admit any wrongdoing on your behalf,
without your written consent. However, the aforesaid will not prevent the Company, to come to a financial arrangement with a plaintiff
in a civil proceeding without your consent so long as such arrangement will not be an admittance of an occurrence not fully indemnifiable
pursuant to this Indemnification Letter or pursuant to law and further provided that any such settlement or arrangement does not
impose on you any liability or limitation. The Company shall not, without your prior written consent, consent to the entry of
any judgment against you or enter into any settlement or compromise which (i) includes an admission of your fault, (ii) does not
include, as an unconditional term thereof, the full release of you from all liability in respect of such proceeding or (iii) is
not fully indemnifiable pursuant to this Indemnification Letter and pursuant to law.

 

12.5. Notwithstanding the above, (i) if in a proceeding to which you are a party by reason of your status as a director or officer
of the Company and the named parties to any such proceeding include both you and the Company or any subsidiary of the Company,
a conflict of interest or potential conflict of interest (including the availability to the Company and its subsidiary, on the
one hand, and you, on the other hand, of different or inconsistent defenses or counterclaims) exists between you and the Company,
or (ii) if the Company fails to assume the defense of such proceeding in a timely manner, you shall be entitled to be represented
by separate legal counsel, which shall represent other persons similarly situated, of the Company’s choice (if the Company
selects such counsel in a timely manner) and reasonably acceptable to you and other person’s choice, at the expense of the
Company. In addition, if the Company fails to comply with any of its material obligations under this Letter of Indemnification,
or in the event that the Company or any other person takes any action to declare this Letter of Indemnification void or unenforceable,
or institutes any action, suit or proceeding to deny or to recover from you the benefits intended to be provided to you hereunder,
except with respect to such actions, suits or proceedings brought by the Company that are resolved in favor of the Company, you
shall have the right to retain counsel of your choice, and reasonably acceptable to the Company and at the expense of the Company,
to represent you in connection with any such matter.

 

12.6. In the event that you make a request for payment of an amount of indemnification hereunder or a request for an advancement
of indemnification expenses hereunder and the Company fails to determine your right to indemnification hereunder or fails to make
such payment or advancement within a reasonably timely manner, you may file a petition with any court which has jurisdiction to
enforce the Company’s obligations hereunder. The Company agrees to reimburse you in full for any reasonable expenses incurred
by you in connection with investigating, preparing for, litigating, defending or settling any action brought by you under the
immediately preceding sentence, provided that the applicable court resolved in favor of you in such claims.

 

     

    - 9  -

    

12.7. You will fully cooperate with the Company and/or any attorney as aforesaid as is reasonably required of you within the
context of their conduct of such legal proceedings, including but not limited to the execution of power(s) of attorney and other
relevant documents, provided that the Company shall cover all costs incidental thereto such that you will not be required to pay
the same or to finance the same yourself.

 

12.8. If, in accordance with Section 12.2, the Company has taken upon itself the conduct of your defense, the Company will have
no liability or obligation pursuant to this Indemnification Letter or the above resolutions to indemnify you for any reasonable
expenses, including any legal fees, that you may expend in connection with your defense, unless (i) the Company shall not have
assumed the conduct of your defense as contemplated in a timely manner (but in any event not later than thirty (30) days from
your written request), (ii) the Company refers the conduct of your defense to an attorney who is not, upon reasonable grounds,
acceptable to you, (iii) the named parties to any such action (including any impleaded parties) include both you and the Company,
and in the Company’s legal counsel’s opinion, joint representation is inappropriate under applicable standards of
professional conduct due to a conflict of interest between you and the Company, or (iv) the Company shall agree to such expenses
in writing, in either of which events you shall be entitled to be represented by separate legal counsel and reasonable fees and
expenses of your counsel shall be borne by the Company. In addition, if the Company fails to comply with any of its material obligations
under this Indemnification Letter, or in the event that the Company or any other person takes any action to declare this Indemnification
Letter void or unenforceable, or institutes any action, suit or proceeding to deny or to recover from you the benefits intended
to be provided to you hereunder, except with respect to such actions, suits or proceedings brought by the Company that are resolved
in favor of the Company, you shall have the right to retain counsel of your choice, and reasonably acceptable to the Company and
at the expense of the Company, to represent you in connection with any such matter.

 

12.9. Except as required pursuant to applicable law, judicial order, regulation or any legal or regulatory proceedings, neither
the Company nor any of its agents, employees, directors or officers shall make any statement to the public or to any other person
regarding any settlement of claims made pursuant to this Indemnification Letter against you that would in any manner be reasonably
be expected to cast any negative light, inference or aspersion against you.

 

12.10. The Company will have no liability or obligation pursuant to this Indemnification Letter to indemnify you for any amount
expended by you pursuant to any compromise or settlement agreement reached in any suit, demand or other proceeding as aforesaid
without the Company’s prior written consent to such compromise or settlement, such consent not to be unreasonably withheld
or delayed.

 

13.             
The Company hereby exempts you as well as releases you, in advance, to the fullest extent permitted by law, from any liability
for damages caused as a result of a breach of your duty of care to the Company, provided that you shall not be exempt with respect
to any action or omission as to which, under applicable law, the Company is not entitled to exculpate you.

 

14.             
If for the validation of any of the undertakings in this Indemnification Letter any act, resolution, approval or other
procedure is required, the Company undertakes to cause them to be done or adopted in a manner which will enable the Company to
fulfill all its undertakings as aforesaid.

 

15.             
Your rights of indemnification hereunder shall not be deemed exclusive of any other rights you may have under the Company’s
Articles of Association, applicable law, any agreement or otherwise.

 

16.             
If any undertaking included in this Indemnification Letter is held invalid or unenforceable, such invalidity or unenforceability
will not affect any of the other undertakings which will remain in full force and effect. Furthermore, if such invalid or unenforceable
undertaking may be modified or 

 

     

    - 10  -

    

amended
so as to be valid and enforceable as a matter of law, such undertaking will be deemed to have been modified or amended, and any
competent court or arbitrator are hereby authorized to modify or amend such undertaking, so as to be valid and enforceable to
the maximum extent permitted by law. Without derogating from the above, In the event of any change, after the date of this Indemnification
Letter, in any applicable law, statute or rule which expands or limits the right of an Israeli company to indemnify its office
holders, such changes shall be, ipso facto, within the purview of your rights and the Company’s obligations, under this
Indemnification Letter.

 

17.             
This Indemnification Letter and the agreements herein shall be governed by and construed and enforced in accordance with
the laws of the State of Israel and the competent courts of Tel-Aviv shall have exclusive jurisdiction over any dispute arising
between the parties with respect of this Indemnification Letter.

 

18.             
The Company undertakes that to the extent that the Company, in any time in the future, shall grant broader indemnification
undertakings to any Office Holders of the Company, such broader indemnification undertakings shall apply to you as well, whether
or not a new indemnification agreement is in effect granted to you.

 

19.             
Neither the settlement nor termination of any proceeding nor the failure of the Company to award indemnification or to
determine that indemnification is payable shall create an adverse presumption that you are not entitled to indemnification hereunder.
In addition, the termination of any proceeding by judgment or order (unless such judgment or order provides so specifically) or
settlement, shall not create a presumption that you did not act in good faith and in a manner which you reasonably believed to
be in or not opposed to the best interests of the Company or, with respect to any criminal action or proceeding, had reasonable
cause to believe that your action was unlawful.

 

20.             
No waiver of any of the provisions of this Indemnification Letter shall be deemed or shall constitute a waiver of any other
provisions of this Indemnification Letter (whether or not similar), nor shall such waiver constitute a continuing waiver. Any
waiver shall be in writing.

 

21.             
This Indemnification Letter constitutes the entire agreement between the parties with respect to its subject matter, and
supersedes and cancels all prior agreements, proposals, representations and communications between the parties regarding the subject
matter hereof. Notwithstanding the foregoing or anything herein to the contrary, your rights hereunder shall not be deemed exclusive
of any other rights you may have under the Company’s Articles of Association, applicable law or otherwise. 

 

22.             
No amendment, modification, termination or cancellation of this Indemnification Letter shall be effective unless it is
in writing and signed by the parties hereto. 

 

23.             
This Indemnification Letter shall inure to your benefit and to the benefit of your heirs, spouses, personal and legal representatives,
executors and administrators and assigns and shall be binding upon the Company, its successors and assigns, including any direct
or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of
the Company. This Indemnification Letter shall continue for your benefit and your heirs’, spouses, personal and legal representatives’,
executors’ and administrators’ benefit after you cease to be an Office Holder of the Company. 

 

24.             
All notices and other communications required or permitted hereunder shall be in writing, shall be effective when given
and shall in any event be deemed to be given:

 

24.1.   When actually tendered, if hand delivered, or

 

24.2.   Five (5) business days if sent internationally after deposit with the applicable postal service; or 

 

     

    - 11  -

    

24.3.   If sent by facsimile or electronic mail, twenty four (24) hours after it has been transmitted provided that sender has
obtained confirmation of transmission from the transmitting facsimile or electronic mail system. All notices and other communications
required or permitted hereunder shall be addressed if to you, at your address as set forth beneath your signature to this Indemnification
Letter and if to the Company, at the address of its principal corporate offices or at such other address as such party may designate
by ten (10) days’ advance written notice to the other party hereto. For the removal of any doubt, a notice that is defectively
addressed or that otherwise fails to comply with the provisions of this Section 23 shall nevertheless be deemed to have been served
if and when actually received by the addressee.

 

     

    - 12  -

    

Kindly
sign and return the enclosed copy of this letter to acknowledge your agreement to the contents hereof.

 

	 	Very truly yours,
	 	 
	 	 
	 	 
	 	Entera Bio Ltd.

Accepted
and agreed to:

 

_________________________

 

Name:

 

Address:

 

Date:Exhibit 10.13

 

THIS
CONVERTIbLE PROMISSORY NOTE AND LOAN AGREEMENT AND THE SHARES ISSUABLE UPON CONVERSION HEREUNDER HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED
OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE SHARES,
SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT.

 

entera
bio ltd.

fORM
OF Convertible Promissory NOTE and Loan agreement

(THE
“NOTE”)

 

 

	$[___]
	
Issue Date: June 14, 2016

 

 

This
Convertible Promissory Note and Loan Agreement is made and entered into as of June 14, 2016 by and between Entera Bio Ltd., a
company organized under the laws of the State of Israel (the “Company”),
and [___________________] (the “Lender”), and is one of a series of Convertible Promissory Note and Loan Agreements
entered into as of the date hereof by the Company and the other parties thereto (such other parties together with the Lender,
the “Lender Group”),
totaling an aggregate amount of $5.5 million (and together with the Corundum Note an aggregate amount of $6.5 million). Commencing
from the date of the Closing and until 90 days from the date of the Closing, the Company may raise an additional amount of up
to 0.5 million, in one or more additional closing(s), under the terms of this Convertible Promissory Note from certain lenders,
as shall be determined at the sole discretion of the Board.

 

For
good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto, intending to
be legally bound, hereby agree as follows:

 

1.                 
The Loan. Subject to the terms and conditions of this Agreement, at
the Closing (as defined below), the Lender shall lend (the “Loan”)
to the Company the aggregate principal amount of [___] (the “Principal Amount”). Subject to the fulfillment or waiver
of the conditions set forth in Section 10 hereof, the closing of the Loan (“Closing”)
shall take place simultaneously upon the execution and delivery by the Lender and the Company of this Note. The Lender shall pay
the Principal Amount to the Company, by wire transfer to the Company’s bank account designated by the Company to the Lender.
The Principal Amount together with all accrued interest (together, the “Loan Obligations”) shall be pari passu to
all principal and other amounts outstanding under those certain (i) Convertible Financing Agreements entered into by the Company
with the other parties thereto (cumulatively, the “Convertible Financing Agreements”) in the  total principal
amounts of $1.15 million as described in Note 7 to the Company’s financial statements for the fiscal year ended December
31, 2014, (ii) Convertible Promissory Note and Loan Agreement entered into by the Company with the other parties thereto in the
total principal amounts of $2.005 million dated August 5, 2015 (the “Original
Convertible Notes”) and (iii) the Convertible Promissory Note and Loan Agreements entered into by the Company
and Corundum Open Innovation Fund, L.P. (“Corundum”),
dated as of the date hereof (the “Corundum
Note”, and together with the Convertible Financing Agreements and the Original Convertible Notes, the “Prior
Notes”).

 

At
the execution of this Agreement, the Company shall deliver to the Lender (i)

 

     

     

    

 

(i)  
a copy of the resolution of the Company’s board of directors (“Board”),
duly approving this Agreement, the Warrant and all the transactions contemplated hereby; (ii) a copy of the resolution of the
shareholders of the Company (x) duly approving the transactions contemplated hereby; (y) amending Article 38(i) of the Fourth
Amended Articles of Association such that the Board will include one additional director to be nominated by Pontifax, on behalf
of the Lender Group as long as the Loan Obligations have not been converted or repaid in full pursuant to the terms of this Note,
provided that following the conversion of this Note into equity securities of the Company in accordance with the terms of this
Note, the Lender Group shall be entitled to appoint one director for so long as it holds one percent (1%) or more of the issued
and outstanding share capital of the Company on a fully-diluted and as-converted basis. The abovementioned right to appoint a
director shall terminate immediately prior to and subject to the closing of the IPO by the Company. In the event of any 30 day
uncured default of payment by the Company under the terms of this Note or any of the Prior Notes, then the holders of a majority
of principal amounts of the Lender Group shall be entitled to nominate, upon written notice to the Company, that number of Board
members to the Board of Directors of the Company determined by multiplying the total number of Board members by a fraction, the
numerator of which shall be the aggregate principal amount of the Lender Group Notes then outstanding and the denominator of which
shall equal the aggregate principal amount of the Lender Group then outstanding plus the principal amount of the Prior Notes then
outstanding; (iii) confirmation by the Company’s CEO that the Company has executed (a) identical convertible promissory
notes (including this Note) with the Lender Group in the aggregate amount equal to $5.5 million or more, and (b) the Corundum
Note with Corundum in the aggregate amount of 1.0 million; and (iv) establishment of an escrow account to be used for the repayment
in full of the outstanding principal amount plus any interest owed at maturity under the Original Convertible Notes (the “Escrowed
Funds”). The Company may convert any or the entire outstanding amounts under the Original Convertible Notes (which for the
avoidance of doubt, shall include the interest accrued thereon as of such time) into the Lender Group Notes at the Closing or
for a period of 15 days following the Closing and the amount of Escrowed Funds will be reduced by the amount of such Original
Convertible Notes that convert into Lender Group Notes with such reduced amount released to the Company for general corporate
purpose use.

 

2.               
Interest. Interest shall accrue on the Principal Amount from the Issue
Date through the Maturity Date at the rate of five percent (5%) per annum. Interest shall be calculated on the basis of the actual
number of days elapsed over a 365-day year. The Loan shall be subject to the היתר עסקה
publicized on http://www.keter.org.il/.

 

3.               
Maturity Date. Unless earlier converted pursuant to Sections 4 or 5
below, the Loan Obligations shall be due and payable in full on December 14, 2017 (“Maturity
Date”), provided, however,
that upon the earlier to occur of (i) maturity of the Original Convertible Notes where the Company is using any of
the Company’s funds in excess of the Escrowed Funds for the payment of principal and interest on the Original Convertible
Notes; or (ii) acceleration of any of the Original Convertible Notes including as a result of the occurrence of an event of default
pursuant to their terms or trigger of an “Insolvency Event” (as defined below), the Loan Obligations shall become
immediately due and payable in full and shall be pari passu to all principal and other amounts outstanding under the Convertible
Financing Agreements, the Original Convertible Notes and the Corundum Note.

 

4.     
Conversion. (a) The Loan Obligations shall be converted as described
in Sections 4(i) or 4(ii) below.

 

		(i)	Conversion
                                         upon Triggering Event. The Note shall be automatically
                                         converted, with no further action required on the part of the Lender, immediately prior
                                         to the consummation of:

 

    2 

     

    

 

		(1)	a
                                         Qualified Financing or a QIPO (each as defined below) occurring prior to the Maturity
                                         Date into that type (or types) and number of (i) equity securities of the most senior
                                         class and/or (ii) securities convertible into equity securities issued by the Company
                                         or sold by the shareholders of the Company in the Triggering Event (the “Applicable
                                         Securities”) (including any warrants or other securities convertible
                                         into Applicable Securities) equal to the Loan Obligations divided by the lesser of (i)
                                         in the case of a Triggering Event - the applicable price per share in the Triggering
                                         Event or in the case of a Voluntary Conversion - the applicable price per share in the
                                         Voluntary Conversion (as applicable for the conversion of the Loan Obligations in the
                                         event of a Voluntary Conversion in accordance with section 4(ii) below) multiplied by
                                         0.75 (the “Discount”)
                                         or (ii) the price per share of such securities calculated at a valuation of the Company
                                         that on a fully diluted basis is equal to $65.0 million (the lower of the two referred
                                         to herein as the “Adjusted
                                         Valuation”); or

 

		(2)	a
                                         Change of Control (as defined below) occurring prior to the Maturity Date into the same
                                         type and amount of consideration that would be received upon the consummation of such
                                         Change of Control (or upon the distribution of the proceeds of such Change of Control
                                         that is an asset transaction) by a holder of Applicable Securities, had the Loan Obligations
                                         been converted into Applicable Securities immediately prior to the Change of Control
                                         at the Adjusted Valuation.

 

For
purposes of this Note: "Triggering Event" means the consummation of the first to occur of a Change of Control, Qualified
Financing or QIPO, occurring following the date of this Note;

 

“Change
of Control” means any (i) acquisition of the Company by another person or group of persons by means of any transaction or
series of related transactions (including, without limitation, any share acquisition, reorganization, merger or consolidation),
other than a transaction or series
of transactions in which the holders of the voting shares of the Company outstanding immediately prior to such transaction continue
to retain (either by such voting shares remaining outstanding or by such voting shares being converted into voting shares of the
surviving entity), as a result of shares in the Company held by such holders prior to such transactions, in substantially the
same proportions, at least fifty percent (50%) of the total voting power represented by the voting shares of the Company or such
surviving entity outstanding immediately after such transaction or series of transactions, or (ii) sale, lease or other conveyance
of all or substantially all of the assets of the Company other than to
a company in which the holders of the shares hold, in substantially the same proportions, at least fifty percent (50%)
of the total voting power represented by the voting shares of the Company;

 

    3 

     

    

 

“Qualified
Financing” means a private placement or series of private placements (under the same terms and provided all such placements
occur within a six month period) of equity securities of the Company, or securities convertible into equity securities of the
Company, in an aggregate amount of no less than $10.0 million not including issuances of securities, the conversion of securities,
or private placements, in any such case pursuant to agreements in effect on the date hereof; and

 

(3)
“QIPO” means the initial underwritten public offering on a firm commitment basis pursuant to a registration statement
filed with the Securities and Exchange Commission under the Act pursuant to which the Company’s Ordinary Shares shall be
listed for trading on the NASDAQ or AMEX and in which the aggregate proceeds (before deduction of underwriters’ discounts
and commissions) equals or exceeds $20.0 million.

 

(ii)  
Voluntary Conversion

 

Notwithstanding
any other provision of this Note, at any time following the date hereof until such time as the then-outstanding Loan Obligations
have been paid by the Company in full (including at any time after 30 days following the failure to make all payments of principal
and interest at the Maturity Date as part of the investment round contemplated below), the Lender has the right, in its sole discretion,
but not the obligation, to choose to convert the Loan Obligations into the most senior class of securities of the Company to be
issued as part of an investment or series of investments of between $4 million and $10 million (including the right to acquire
any convertible securities that were acquired by the holders of such securities upon acquisition of such securities) with identical
rights and preferences, at a conversion price per share equal to the price per share of such securities calculated assuming a
valuation of the Company (on a fully diluted basis) equal to the Adjusted Valuation (such conversion, the “Voluntary
Conversion”).

 

(b)  
Investors Rights Agreement. Upon conversion of the Note, the Lender
shall execute a joinder to the Amended and Restated Investors' Rights Agreement among the Company and the other parties thereto,
as the same may be amended from time to time, as though an original party thereto and shall be bound by all of the terms and conditions
thereof, including but not limited to Section 2.10 (Lock-Up) thereof.

 

(c)  
Mechanics. The person or persons in whose name(s) any certificate(s)
representing all shares of the Company issued or acquired upon conversion of this Note

 

(collectively,
the “Securities”)
shall be deemed to have become the holder(s) of record of, and shall be treated for all purposes as the record holder(s) of, the
Securities represented thereby (and such Securities shall be deemed to have been issued) immediately prior to the close of business
on the date or dates upon which this Note is converted, and certificates for such Securities shall be delivered to the Lender
as soon as possible and in any event within thirty (30) days after such conversion.

 

(d)  
No Fractional Shares. No fractional shares will be issued in connection
with any conversion hereunder, but in lieu of such fractional shares the Company shall round up or down to the nearest whole number
of shares (in the event any such fraction is equal to one-half (1/2), the Company shall round up to the nearest whole number)
and issue such whole number of shares.

 

(e)  
The Securities shall be of the same class or series and shall have the same applicable rights and preferences as the most
senior class of shares issued by the Company to the investors in the Triggering Event or acquired by the Lender upon Voluntary
Conversion, as applicable (“Senior

 

    4 

     

    

 

Shares”),
including without limitation, liquidation preference, anti-dilution protection, registration rights, preemptive rights, right
of first refusal, voting and other rights, pro-rata to the respective amounts of investment but excluding veto rights, and in
the event of a conversion pursuant to Section 4(a)(i) above (provided such rights shall not be deemed to include the warrants
issued by the Company prior to the date hereof or any veto rights of Centillion Fund, Inc.) Lender shall otherwise be deemed an
investor in such event in which the applicable Senior Shares were issued, for all purposes pro-rata as adjusted for the Discount
to the respective amounts of investment (including with respect to any other securities, warrants or other rights issued or provided
to such investors). Notwithstanding anything herein to the contrary, the Original Issue Price (as such term is defined in the
Company’s Fourth Amended and Restated Articles of Association, as amended and as the same may be amended from time to time
(the “Articles”))
for each of the shares issued and converted pursuant to this Section 4 shall be equal to the price per share paid hereunder by
the Lender for such shares.

 

(f)   
Notice. Without limiting any other rights the Lender may have under
this Agreement, for as long as any part of the Loan remains outstanding, the Company shall deliver prior written notice to the
Lender of any contemplated Triggering Event or any financing of the Company, as promptly as possible, but in any event at least
ten (10) days prior to the closing of such transaction, specifying the terms and conditions of such transaction (“Transaction
Notice”).

 

(g)  
In the event that on or prior to the Maturity Date or the date of conversion pursuant to this Section 4, the Company shall
grant any lender preferential rights, then this Note shall be automatically amended to include such preferential rights.

 

5.                 
No Prepayment. Upon the written consent of Pontifax (Israel) IV Fund
L.P.; Pontifax (Cayman) IV Fund L.P.; and Pontifax (China) Fund L.P. (collectively, “Pontifax”)
and the Company, the Company shall be entitled to prepay the Loan Obligations prior to the earlier of (i) the conversion of the
Note pursuant to Section 4 above; or (ii) the Maturity Date.

 

6.                 
Default. Subject to Section 3 above, in the event that any of the events
specified in this Section 6 (each an “Event
of Default”) shall occur prior to the conversion of this Note or the repayment of the Principal Amount and all
accrued interest, all Loan Obligations shall become immediately due and payable prior, and the Loan Obligations shall be pari
passu to any other payments, debts or distributions due from the Company under the Prior Notes:

 

(a)   
The Company shall fail to perform any material obligation or undertaking of the Company under this Note and such failure
shall continue to uncured for a period of ten (10) business days following receipt of notice from the Lender; or

 

(b)  
(i) The Company files a petition for voluntary dissolution or seeking any reorganization (excluding the Reincorporation,
as such term is defined below), arrangement, composition or any other similar relief under any law regarding insolvency or relief
of debtors,

 

(ii)  
any involuntary liquidation or dissolution proceedings or acts of bankruptcy are instituted against the Company, and such
actions are not stayed, enjoined, or discharged within sixty (60) days from their commencement, (iii) a receiver, trustee, or
similar officer is appointed for the business or a significant part of the property of the Company, and such appointments are
not stayed, enjoined, or discharged within sixty (60) days from their commencement, (iv) the Company makes a general assignment
for the benefit of its creditors, (v) the Company adopts a resolution for discontinuance of its business or for its liquidation,
dissolution or winding-up, or (vi) the Company admits in writing that it is generally unable to pay its debts as they become due
(any of (i) through (vi) above, an “Insolvency
Event”).

 

    5 

     

    

 

Immediately
upon the occurrence of any such Event of Default, the Company shall notify the Lender of such Event of Default setting forth the
details of such Event of Default.

 

7.                 
Warrant; Right to Purchase Additional Shares of the Company. Upon execution
of this Note, the Company shall issue to the Lender a warrant to purchase shares of the Company, on the terms and conditions set
forth in the warrant agreement in the form attached hereto as Schedule
A (the “Warrant”).
In addition, the Lender shall be entitled to invest up to $[___] in the next share issuance by the Company (provided that the
Company and the Lender may mutually agree on a greater amount).

 

8.                 
Representations and Warranties of the Company. The Company represents
and warrants to the Lender that:

 

(b)  
Organization. The Company is duly organized and validly existing under
the laws of the State of Israel, and has full corporate power and authority to own, lease and operate its properties and assets
and to conduct its business as now being conducted and as presently proposed to be conducted and the Company is not in material
default under any permit to do business. The Company has all requisite power and authority to execute and deliver this Note and
to consummate the transactions and perform its obligations contemplated hereby.

 

(c)   
Authority. The authorization, execution, delivery and performance by
the Company of this Note and the Warrant and the consummation of the transactions contemplated hereby have been duly authorized
by all necessary corporate action.

 

(d)  
Enforceability. The Note and the Warrant have been duly executed and
delivered by the Company and, assuming the execution and delivery of this Note and the Warrant by the Lender, constitutes a legal,
valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as limited by
bankruptcy, insolvency or other laws

 

of
general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity.

 

(e)  
Non-Contravention. The Company is not in violation or default of any
term of the Articles, of any provision of any mortgage, indenture, agreement, instrument or contract to which it is party or by
which it is bound or to its knowledge of any judgment, decree, order or writ. The execution and delivery by the Company of this
Note and the Warrant and the performance and consummation of the transactions contemplated hereby do not and will not (i) violate
the Articles or any material judgment, order, writ, decree, law, statute, rule or regulation applicable to the Company; (ii) violate
any provision of, or result in the breach or the acceleration of, or entitle any other person to accelerate (whether after the
giving of notice or lapse of time or both), any material mortgage, indenture, agreement, instrument or contract to which the Company
is a party or by which it or any of its property is bound; or (iii) result in the creation or imposition of any Lien (as defined
herein) upon any material property, asset or revenue of the Company or the suspension, revocation, impairment, forfeiture, or
nonrenewal of any material permit, license, authorization or approval applicable to the Company, its business or operations, or
any of its material assets or properties. “Lien”
shall mean, with respect to any property, any security interest, mortgage, pledge, lien, claim, charge or other encumbrance in,
of, or on such property or the income therefrom.

 

(f)   
Approvals. No consent, approval, order, license, permit, action by,
or authorization of, or designation or declaration with any governmental authority or other person (including, without limitation,
the shareholders of any person) is required in connection with the execution and delivery of

 

    6 

     

    

 

this Note and the Warrant executed by the Company and the performance and consummation of the transactions contemplated hereby
(including the issuance of Securities upon conversion of the Loan Obligations and/or upon execution of the Warrant, other than
the execution by the Lender of the undertaking to the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor,
If required according to the provisions of the Israeli Encouragement of Research and Development in Industry Law 5744-1984).

 

(g)  
Shares. The registered and authorized share capital of the Company
as of the Issue Date is one million (1,000,000) Ordinary Shares and twenty-five thousand (25,000) Series A Preferred Shares. Schedule
8(g)-1 contains a true and correct description of the identity of each holder of shares and other securities of the
Company, including the number of such shares and securities held thereby, the “Capitalization
Table”). Except as set forth in the Capitalization Table and except as set forth on Schedule
8(g)-2 attached hereto, there are no other share capital, outstanding preemptive rights, convertible securities, warrants,
options or other rights to subscribe for, purchase or acquire from the Company (or to the knowledge of the Company, from any shareholder
of the Company) any share capital of the Company, and there are no contracts or binding commitments providing for the issuance
of, or the granting of rights to acquire, any share capital of the Company or under which the Company is obligated to issue, sell,
transfer or otherwise cause to be issued, sold, transferred or otherwise any of the Company's securities. All issued and outstanding
share capital of the Company has been duly authorized in compliance with all applicable laws, and is validly issued and outstanding
and fully paid and nonassessable.

 

(h)  
Litigation. There is no action, proceeding, claim, or (to the knowledge
of the Company) governmental inquiry or investigation pending or threatened against the Company or

 

any
of its officers, directors, or employees (in their capacity as such), or against any of the Company's properties and to the Company’s
knowledge there is no basis for any such claim. There is no action, suit, proceeding or investigation by the Company pending or
which the Company intends to initiate.

 

(i)    
Financial Statements. The Company’s audited financial statements
as of December 31, 2014 and audited financial reports as of December 31, 2015 are attached hereto as Schedule
8(o) (together, the “Financial
Statements”). The Financial Statements have been prepared in accordance with International Financial Reporting
Standards (IFRS) applied on a consistent basis throughout the periods indicated. The Financial Statements fairly present in all
material respects the Company’s financial condition for the periods indicated. Except as set forth in the Financial Statements,
the Company has no material liabilities or obligations, contingent or otherwise, other than (i) liabilities incurred in the ordinary
course of business subsequent to December 31, 2015 (including, but not limited to, the Corundum Note, (ii) obligations under contracts
and commitments incurred in the ordinary course of business, (iii) liabilities and obligations of a type or nature not required
under IFRS to be reflected in the Financial Statements, or (iv) as set forth in Schedule
8(o)(2).

 

(j)
Taxes. As of the date hereof the
Company has no outstanding liability for taxes, except for taxes the payment of which is not yet due or for which the Company
has made adequate and sufficient provisions in its financial statements.

 

(k)
Intellectual Property.

 

    7 

     

    

 

		i.	Except
                                         as set forth on Schedule 8(k), the Company is the sole owner of the entire right, title
                                         and interest in and to, and has developed, or has obtained the right to use, free and
                                         clear of all Third Party Rights, all Intellectual Property (as defined below), used in
                                         the conduct of its business as now conducted and as currently proposed to be conducted,
                                         without (to the knowledge of the Company) infringing upon or violating any third party
                                         right of others. Schedule
                                         8(k) lists the patents and provisional patents owned or used by the Company
                                         in its business as currently conducted and all patent applications filed by the Company.
                                         To the Company’s best knowledge, there are no claims or demands pending by any
                                         other person pertaining to any of such Intellectual Property nor is there a claim or
                                         demand threatened, and no proceedings have been instituted or threatened which challenge
                                         the rights of the Company with respect to such Intellectual Property and the Company
                                         does not believe there is any reasonable basis for such claim.

 

		ii.	Each
                                         of the Company’s current and former employees, who, either alone or in concert
                                         with others, developed, invented, discovered, derived, programmed or designed the Intellectual
                                         Property or who have knowledge of or access to information about the Intellectual Property,
                                         has entered into a written agreement with the Company, assigning to the Company all

 

rights
in intellectual property developed in the course of their employment by or consultancy to the Company.

 

		iii.	The
                                         Company has not violated or by conducting its business as conducted or currently proposed
                                         to be conducted, would not violate, any of the patents, trademarks, service marks, trade
                                         names, copyrights or trade secrets or other proprietary rights of any other person or
                                         entity and (to the knowledge of the Company) no person or entity is engaging in any activity
                                         that infringes or violates the Company’s Intellectual Property. No action, suit,
                                         proceeding, hearing, investigation (to the Company’s knowledge), charge, complaint,
                                         or demand is pending which challenges the legality, validity, enforceability, use, or
                                         ownership of any of the Intellectual Property and the Company was not served with any
                                         written notice relating to the intention of any party to commence such actions.

 

		iv.	As
                                         used in this Note, the term “Intellectual Property” shall mean (1) inventions
                                         (whether or not patentable), trade secrets, technical data, databases, customer lists,
                                         designs, tools, methods, processes, technology, ideas, know-how and other confidential
                                         or proprietary information and materials; (2) trademarks and service marks (whether or
                                         not registered), applications for trademarks and service marks, trade names, logos, trade
                                         dress and other proprietary indicia and all goodwill associated therewith;

 

(3)  
documentation, specifications, mask works, drawings, graphics, databases, recordings and other works of authorship, whether
or not protected by copyright; (4) source code, object code, data and operating files, user manuals, documentation, flow charts,
algorithms, compilers, development tools, maintenance records and other materials related to computer programs; (5) internet web-sites
and domain names; and (6) all forms of legal rights and protections that may be obtained for, or may pertain to, the Intellectual

 

    8 

     

    

 

Property set forth in clauses (1) through (5) in any country of the world, including, without limitation, all letters patent,
patent applications, provisional patents, design patents, PCT filings and other rights to inventions or designs, all registered
and unregistered copyrights in both published and unpublished works, trade secret rights, mask works, moral rights or other literary
property or authors rights, rights regarding trademarks and other proprietary indicia, and all applications, registrations, issuances,
divisions, continuations, renewals, reinsurances and extensions of the foregoing.

 

(l)
Full Disclosure. Neither this
Agreement nor any certificate or document made, delivered or made available by the Company in connection herewith (including,
without limitation, all such documents made available in the data room made available by the Company to the Lender Group in connection
herewith located at

 

https://www.dropbox.com/sh/9fxi459ipewbi2x/AABkFc06xiUxKStLptLvB1yCa7dH0
and https://www.dropbox.com/sh/qx3wk6uhu0m25d8/AACfKSxsl1ZvKi9WQJbtuc1ha7dH0)
contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements
herein or therein not misleading. The Lender has the right to rely fully upon the representations, warranties, covenants and agreements
of the Company contained in this Section.

 

9.     
Representations and Warranties of the Lender.

 

By
the acceptance of this Note, the Lender represents and warrants to the Company that:

 

(a)  
The Lender is acquiring this Note and the Warrant for Lender’s own account for investment and not with a view to
or for sale in connection with any distribution, and all Securities will also be acquired for Lender’s own account, for
investment and not with a view to, or for sale in connection with any distribution.

 

(b)  
The Lender was contacted directly by the Company and/or its representatives regarding engaging in the transactions contemplated
by this Note and the Warrant or a similar financing transaction with the Company, and was not initially notified about the Company
or a potential transaction with the Company via any public announcement or publication regarding an intended public offering of
the Company's securities.

 

(c)  
The Lender understands that the Securities and the Warrant may not be sold, transferred, assigned, pledged, or otherwise
disposed of unless the Securities or the Warrant (as applicable) are registered under the Act, and all applicable state securities
laws or unless exemptions from such registration requirements are available.

 

(d)  
The Lender is an experienced investor in securities of companies in an early development stage and acknowledges that it
is able to fend for itself, can bear the economic risks of such investment (including the complete loss thereof) and has such
knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of this investment.
The Lender has been afforded the opportunity to ask questions to officers or other representatives of the Company concerning the
business of the Company, and it has reviewed and inspected all of the data and information provided to it by the Company in connection
with this Note. The Lender is (i) an “accredited investor” within the meaning of Rule 501 of Regulation D promulgated
under the Act and/or (ii) a non-“U.S. person” within the meaning of Rule 902(k) promulgated under the Securities Act
(and the Lender is not engaging in the transactions hereunder for the account or benefit of a U.S. Person) and at the time of
the offer and sale of the Note and the Warrant the Lender was not located in the United States.

 

    9 

     

    

 

(e)  
The Lender understands that any permitted successor holder or transferee of the Securities will be required to provide
to the Company the representations and warranties contained in this Section 9.

 

(f)   
The Lender understands that the Securities and the Warrant have not been, and will not be, registered under the Act, or
any state securities law, based on an exemption or exemptions provided thereunder, the availability of which depends upon, among
other things, the bona fide nature of the investment intent and the accuracy of such Lender’s representations as expressed
herein, and will be “restricted securities” within the meaning of Rule 144 promulgated under the Act; and that all
stock certificates representing Securities may have affixed thereto a legend substantially in the following form.

 

THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN

 

REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED
FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR UNLESS SUCH
TRANSFER IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. THE COMPANY MAY REQUIRE
AN OPINION OF COUNSEL, IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY, TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED
IN CONNECTION WITH SUCH TRANSFER.

 

10.            
Conditions to the Parties’ Obligations. The obligations of the
Lender and the Company under this Agreement are subject to the fulfillment of each of the following conditions, at or before the
Closing, unless otherwise waived by the parties hereto, as applicable:

 

(a)  
Waivers of Pre-emptive Rights. Any pre-emptive or other participation
rights of any person other than the Lender to participate in the lending of such Lender's Loan and in the issuances of the Company’s
Securities upon conversion of the Principal Amount and accrued interest and in the issuance of the Company's Securities upon execution
of the Warrant, as may exist pursuant to the Articles or any other agreements between the Company and its shareholders, shall
have been properly waived.

 

(b)  
Corporate Approvals. The board of directors of the Company shall have
approved this Agreement, the Warrants and all the transactions contemplated hereby

 

(c)   
Warrant. The executed Warrant shall have been delivered to the Lender.

 

11.            
Covenants of the Company. The Company hereby covenants to the Lender
that, promptly following the Closing and subject to all applicable law and receipt of all necessary approvals and consents, it
shall use its reasonable efforts to reincorporate within a jurisdiction in the United States (the “Reincorporation”),
which such reincorporation may be effected pursuant to a merger of the Company with an affiliated entity of the Company that is
incorporated in the United States following which such affiliated entity would hold all the outstanding shares of the Company,
and the Lender agrees to exchange this Note and the Warrant being issued in connection herewith for a note and warrant to be issued
on substantially the same terms and conditions hereof and thereof to be issued by the U.S. entity following the Reincorporation.

 

    10 

     

    

 

12.            
Restrictions on Transfer. This Note and the obligations under this
Note may not be assigned by the Company without the prior written consent of the Lender. By acceptance of this Note, the Lender
hereby agrees that (i) until the consummation of the IPO, the Lender will not sell, offer for sale, pledge, hypothecate or otherwise
transfer “Transfer”)
this Note or the Securities except in accordance with the Articles and (ii) upon and following the consummation of an IPO, absent
an effective registration statement filed with the Securities and Exchange Commission under the Act covering the disposition or
sale of this Note or the Securities, as the case may be, and registration or qualification under applicable state securities laws,
the Lender will not Transfer any or all of this Note or the Securities, as the case may be, unless such Transfer is exempt from
the registration requirements of the Act and any applicable state securities laws, and in such event the Company may reasonably
require an opinion of counsel, in form and substance reasonably satisfactory to the Company, to the effect that such registration
is not required in connection with such transfer except in accordance with the Articles.

 

13.           
Shares Fully Paid; Reservation of Securities. All Securities that may
be issued upon the conversion of this Note and upon conversion of the Warrant will, upon issuance pursuant to the terms and conditions
herein, be fully paid and nonassessable, and free from all preemptive rights and taxes, liens and charges with respect to the
issuance thereof. Upon any event in which Securities are issued to the Lender (under this Note and/or under the Warrant), the
Company will have authorized and reserved for the purpose of the issue upon conversion of this Note and/or the Warrant, as applicable,
a sufficient number of Securities to provide for the conversion of this Note and Warrant and, in the event that the Applicable
Securities are convertible preferred shares, a sufficient number of Ordinary Shares of the Company to provide for the conversion
of the Applicable Securities into Ordinary Shares of the Company.

 

14.           
Taxes; Withholding. Any taxes, fees, levies, duties, surcharges or
withholdings of any nature imposed by any governmental authority or third party owed on the interest or the Discount shall be
the sole liability and responsibility of the Lender. Notwithstanding the foregoing, any payment by the Company of interest hereunder
shall be subject to applicable withholding tax, which shall be withheld and deducted by the Company unless the Company is provided
with a certificate evidencing any valid exemption from such deduction or withholding. Any value added tax to be paid by the Company
in connection with the transactions hereunder (including but not limited to payment of any interest due hereunder) shall be paid
by the Company upon receipt of a valid value added tax invoice.

 

15.            
Designation of Observer.

 

The
holder of the then-largest amount of outstanding principal and accrued but unpaid interest among the Original Convertible Notes,
the Corundum Note and the Lender Group shall have the right to designate, dismiss and replace one (1) representative (the “Observer”),
who (subject to the Observer entering into a confidentiality and non-compete undertaking with the Company) shall be entitled to
attend all meetings of the Board in a non-voting observer capacity, to receive notice of such meetings and to receive any and
all documentation, information and/or other materials provided to the members of the Board and in addition the Observer shall
be entitled to request and receive from the Company any documentation, information and/or other materials that any of the members
of the Board is or may be entitled to receive from the Company. Any materials furnished to the Observer and the discussions and
presentations in connection with or at any meeting shall be considered confidential information and the Observer will keep such
materials and discussions confidential and will not disclose or divulge such materials and discussions to any third party. Notwithstanding
the above, the Company shall not be obligated to provide access to any information or meeting of the Board that will impair attorney-client
privileges between the Company and its counsel, or which constitutes a conflict of interest, such determination made reasonably
by the Board, acting in good faith.

 

    11 

     

    

 

16.           
Expenses. Each of the Company and the Lender Group shall pay all costs
and expenses that it incurs with respect to the negotiation, due diligence investigation, execution, delivery and performance
of this Note; provided that upon the consummation of the Closing, the Company shall bear all legal and accounting fees and other
expenses (e.g. costs of due diligence) incurred by the Lender Group in connection with the transactions contemplated by this Note,
in the amount of up to US$ 18,000 plus V.A.T. Pontifax may deduct such amount from the Loan Amount transferred by it at the Closing.

 

17.             
Miscellaneous.

 

a.    
Notices. Any notice, request, communication or other document required
or permitted to be given or delivered to the Lender or the Company shall be delivered, or shall be sent by certified or registered
mail, postage prepaid, overnight courier or facsimile (with return receipt requested) or delivered personally to the Lender at
its address as shown on the signature page hereto or to the Company at the address indicated therefor on the signature page of
this Note.

 

b.   
Governing Law; Jurisdiction. This Note and all acts and transactions
pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted solely in accordance
with the laws of the State of Israel, without giving effect to its conflict of laws principles. Any dispute arising under or in
relation to this Note shall be resolved exclusively by the competent courts of Tel-Aviv Jaffa and each of the parties hereby irrevocably
submits to the exclusive jurisdiction of such courts.

 

c.    
Successors and Assigns. This Note, and the obligations and rights of
the Company hereunder, shall be binding on and inure to the benefit of the Company, the Lender, and their respective permitted
successors, assigns, heirs and beneficiaries. Without limiting the foregoing, any successor, assign, heir or beneficiary of a
Lender shall be subject to the terms of this Note, including the limitations on transfer and the representations contained in
this Note.

 

d.   
Amendments and Waivers; Delays or Omissions. Any term of this Note
may be amended only by an instrument in writing executed by the Company and Pontifax on behalf of the Lender Group. The compliance
with any provision or condition of this Note, and any breach or default thereof, may be waived only with the written consent of
the Company or the Lender. Any waiver on the part of any party of any provision, condition, breach or default under this Note
shall be effective only to the extent specifically set forth in such writing. No delay or omission to exercise any right, power
or remedy accruing to any party upon any breach or default under this Note shall impair any such right, power or remedy nor shall
it be construed to be a waiver of any such breach or default, or an acquiescence thereto, or of any subsequent breach or default;
nor shall any waiver of any single breach or default be deemed a waiver of any other prior or subsequent breach or default.

 

e.    
Severability. If one or more provisions of this Note are held to be
unenforceable under applicable law, such provision shall be excluded from this Note, and the remainder of this Note shall be enforceable
in accordance with its terms.

 

    12 

     

    

 

f.    
Entire Agreement. This Note constitutes the entire agreement between
the parties pertaining to the subject matter contained herein and supersedes all prior and contemporaneous agreements, representations,
and undertakings of the parties, whether oral or written, with respect to such subject matter.

 

g.    
Counterparts. This Note may be executed in one or more counterparts,
each of which shall be deemed an original and all of which together shall constitute one instrument. Facsimile signatures shall
be binding as original signatures.

 

[Signature
page follows]

 

 

    13 

     

    

IN
WITNESS WHEREOF, this Note has been executed and delivered on the date first above written.

 

 

	 	ENTERA
BIO LTD.	 
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 	 	 
	 	Entera
Bio Ltd.

Jerusalem Bio Park

PO
Box 12117

Jerusalem
91220

Fax
no.: +972.2. 532.7151

Attn:
Dr. Phillip Schwartz

	 

 

 

 

 

 

 

 

 

[Company
signature page to Convertible Promissory Note and Loan Agreement]

 

    14 

     

    

 

Accepted
and Agreed to by:

 

	 	 
	 	 
	 	 

[Address]

 

 

[Lender’s
signature page to Convertible Promissory Note and Loan Agreement]

 

    15 

     

    

Schedule
of Lenders to the Convertible Promissory Note and Loan Agreement 

dated as of June 14, 2016

 

	Lender	Principal
    Amount ($)
	Ari
    Bernstein	15,000.00
	Ari
    Bernstein	25,806.50
	Arik
    Kaufman	25,806.50
	BellCo
    Capital, LLC	150,000.00
	Bonderman
    Family Limited Partnership	1,000,000.00
	Corundum
    Open Innovation Fund, L.P.	1,000,000.00
	Daniel
    Kaufthal	100,000.00
	David
    Tenan (Trustee)	300,000.00
	Eton
    Street Holdings, LLC	150,000.00
	Gerald
    Lieberman	51,613.01
	Gerald
    Lieberman	50,000.00
	Greg
    Kiernan	300,000.00
	Ilan
    Kaufthal	250,000.00
	Joshua
    Kazam (Trustee)	300,000.00
	Kenneth
    Abramowitz	51,012.00
	Luke
    M. Beshar	50,000.00
	Mainfield
    Enterprises Inc.	774,195.21
	Menachem
    Raphael	600,000.00
	Pontifax
    (Cayman) IV Fund L.P.	720,350.67
	Pontifax
    (China) IV Fund L.P.	800,000.00
	Pontifax
    (Israel)	1,479,649.33
	Roger
    J. Garceau	25,000.00
	Seaview
    Trust	150,000.00
	Victor
    Tshuva	25,806.50
	White
    Car Group Ltd.	103,226.03

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]